2seventy bio is an immuno-oncology cell therapy company that discovers and develops therapies used for cancer treatment.
2seventy bio is an immuno-oncology cell therapy company that discovers and develops therapies used for cancer treatment. The company combines a deep knowledge of cancer cell biology and genetics with an understanding of the immune response to cancer to advance its pipeline.It was established in Cambridge, Massachusetts in 2021.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 6, 2023 | Post-IPO Equity | $20M | 1 | Regeneron | — | Detail |
Mar 16, 2022 | Post-IPO Equity | $170M | 2 | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Feb 15, 2022
Cohere
|
Series B | $159M | Artificial Intelligence | — |
Jan 17, 2022
Wayve
|
Series B | $200M | Artificial Intelligence | — |
Sep 7, 2021
Cohere
|
Series A | $40M | Artificial Intelligence | — |
Jun 8, 2021
Waabi
|
Series A | $100M | Artificial Intelligence | — |
Jul 1, 2019
Wayve
|
Series A | $20M | Artificial Intelligence | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Regeneron | Yes | Post-IPO Equity |
Newtyn Management | — | Post-IPO Equity |
Nick Leschly & family | — | Post-IPO Equity |